Concurrent chemoradiotherapy improves prognosis and quality of life of patients with metastatic and recurrent hepatocellular carcinoma.

Shugang Sun, Bin Shen, Ning Wang

Abstract read

In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Construction and validation of a predictive model for the risk of malnutrition in hospitalized patients over 65 years of age with malignant tumours: a single-centre retrospective cross-sectional study.PeerJ · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shugang SunDepartment of General Surgery, Affiliated Hospital of Hebei Engineering University Handan 056000, Hebei, China.

Bin ShenDepartment of General Surgery, Affiliated Hospital of Hebei Engineering University Handan 056000, Hebei, China.

Ning WangDepartment of Obstetrics and Gynecology, Affiliated Hospital of Hebei Engineering University Handan 056000, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study retrospectively analyzed the effect of concurrent chemoradiotherapy on prognosis and quality of life of patients with metastatic and recurrent hepatocellular carcinoma (HCC).

methodsThis is a retrospective analysis. Data from 60 patients with metastatic and recurrent HCC admitted from Oct. 2020 to Feb. 2021 were chosen and grouped according to the treatment plans. Each group contained 30 cases. The control group was treated with chemotherapy, and the observation group received concurrent chemoradiotherapy. The two groups were treated continuously for two rounds, with 21 days in each round. The therapeutic efficacy, toxic side effects, pre- and post-treatment quality of life, changes in vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2), and survival during follow-up were compared between the two groups.

resultsThe total therapeutic efficacy of the observation group was higher than that of the control group (

conclusionConcurrent chemoradiotherapy has good short-term and long-term efficacy for patients with metastatic and recurrent HCC. It greatly improves patients' quality of life and down-regulates VEGF and COX-2 expression.

Indexed as

Concurrent chemoradiotherapyhepatocellular carcinomametastasisprognosisquality of liferecurrence

Identifiers

PMID36777829

PMCPMC9908489

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.